An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses
Science Immunology · 06.06.2025 · 10 (108)
DOI: 10.1126/sciimmunol.ads1328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 06.06.2025. Verfasst von Emily A Aunins und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Interleukin-12, Nanoparticles, Adjuvants, Immunologic. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Optimizing vaccine design to induce CD8 T cell responses has been challenging, but lipid nanoparticle (LNP)–encapsulated mRNA vaccines effectively generate CD8 T cell memory. Interleukin-12 (IL-12) supports CD8 T cell expansion and acquisition of effector function, but the role of IL-12 in the generation of CD8 T responses to mRNA vaccination is unclear. Here, we determine that endogenous IL-12 is not required for CD8 T cell responses to mRNA-LNP vaccination. We assessed the adjuvant activity of an mRNA-LNP encapsulating a codon-optimized mRNA that encodes both subunits of IL-12 (LNP–IL-12). Coadministration of LNP–IL-12 with ovalbumin (OVA) mRNA-LNPs enhanced CD8 T cell expansion and effector function and expanded circulating, effector, and tissue-resident memory CD8 T cells. LNP–IL-12 increased CD8 T cell responses against SARS-CoV-2 and influenza virus antigens and improved protection against Listeria monocytogenes –OVA and B16F0-OVA melanoma. Thus, modification of mRNA-LNP formulations to include a cytokine mRNA provides a strategy to enhance CD8 T cell–mediated protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Department of Medicine, Infectious Disease Division, University of Pennsylvania, Philadelphia, PA, USA.
- Penn Institute for RNA Innovation, University of Pennsylvania, Philadelphia, PA, USA.
- Acuitas Therapeutics, Vancouver, BC V6T 1Z3, Canada.
ORCID-Profile: Emily A Aunins, Anthony T Phan, Mohamad-Gabriel Alameh, David A Christian, Ying Tam, Molly E Bunkofske, Keenan M O'Dea, Maria Merolle, Phillip Scott, Robert H Vonderheide, Scott E Hensley, Ross M Kedl, Drew Weissman, Christopher A Hunter
Förderung
- NIAID NIH HHS
- NCI NIH HHS
Zitieren
APA
Aunins, E. A., Phan, A. T., Alameh, M. G., Dwivedi, G., Cruz-Morales, E., Christian, D. A., Tam, Y., Bunkofske, M. E., Peñafiel, A. Z., O'Dea, K. M., Merolle, M., Furey, C., Scott, P., Vonderheide, R. H., Hensley, S. E., Kedl, R. M., Weissman, D., & Hunter, C. A. (2025). An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses. Science Immunology, 10(108). https://doi.org/10.1126/sciimmunol.ads1328
Vancouver
Aunins EA, Phan AT, Alameh MG, Dwivedi G, Cruz-Morales E, Christian DA, et al. An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses. Science Immunology. 2025;10(108). doi:10.1126/sciimmunol.ads1328
BibTeX
@article{Aunins2025,
author = {Aunins, Emily A and Phan, Anthony T and Alameh, Mohamad-Gabriel and Dwivedi, Garima and Cruz-Morales, Elisa and Christian, David A and Tam, Ying and Bunkofske, Molly E and Peñafiel, Anabel Zabala and O'Dea, Keenan M and Merolle, Maria and Furey, Colleen and Scott, Phillip and Vonderheide, Robert H and Hensley, Scott E and Kedl, Ross M and Weissman, Drew and Hunter, Christopher A},
title = {An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses},
journal = {Science Immunology},
year = {2025},
volume = {10},
number = {108},
doi = {10.1126/sciimmunol.ads1328}
}
EUVIMED